Make your money go further for just 25p per day

PREMIUM

Mega-Trends: A troubling 2021 opens opportunities for recovery

11/02/2022

Mega trends

Mega-Trends Investor's Champion logo
  • The Mega-Trends portfolio ended 2021 down 4%
  • The portfolio remains on the hunt for exciting innovation which is not yet being recognised by the market 

Without a repeat of star stock Tesla’s (US: TSLA) 2020 portfolio contribution (a 12.5-fold return), the Investor’s Champion Mega-Trends Portfolio struggled to maintain its pace of growth in 2021. After a decent, market-beating start to the year, momentum faltered in March as the tide turned on the high-growth, high-risk sections of the stock market. The portfolio closed the year down 7.3%.

But it’s not all bad news. The original £40,000 investment we made in 20 stocks…

Continue reading our content…

Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • Unlimited access to our market-beating portfolios
  • In-depth coverage of many of the world’s great companies
  • Unique insights from our top research team
Register FREE for access to limited content.
  • Company and markets insights
  • Sponsored content
  • Podcasts

Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Alphabet

Ultimate Stocks Portfolio: tech titan takes a hit and other news

27/10/2023 · Portfolio

Results season has brought impressive results from constituents of our Ultimate Stocks portfolio covered here. However, with…


Ultimate Stocks portfolio update

26/07/2023 · Portfolio

Results from constituents of our Ultimate Stocks portfolio covered here were excellent. Despite strong share price…


More on CRISPR Therapeutics

An immense opportunity

30/08/2022 · Portfolio

CRISPR Therapeutics’ therapy for sickle cell disease could be available next year; this is incredibly exciting…


Mega-Trends: A troubling 2021 opens opportunities for recovery

11/02/2022 · Portfolio

Sign-up to our free email updates

SIGN UP